Novo Nordisk's Wegovy Wins EMA Flexibility In GLP-1 Access Push [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk has received EMA approval to allow Wegovy injections to be stored at up to 30°C for up to 48 hours. The change reduces strict cold chain requirements for pharmacies and online distributors across Europe. Wegovy is now the first GLP-1 weight management treatment in Europe with this level of delivery flexibility. For investors tracking CPSE:NOVO B, this regulatory update comes as the share price stands at DKK260.4. The stock shows mixed performance, with gains of 8.2% over the past week and 7.8% over the past month, but a 21.2% decline year to date and a 35.3% decline over the past year. Over five years, the return is 27.3%, reflecting a longer term gain despite more recent weakness. The EMA decision may support more efficient distribution models for Wegovy, which can matter as GLP-1 competition increases. Investors will likely monitor how this added flexibility relates to patient access, pharmacy and online channel uptake, and Novo Nordisk's position in the weight
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo GLP-1 drug shows less lean mass loss than rivals, study says [USA TODAY]USA TODAY
- Novo obesity drug outperforms Lilly's in preserving lean body mass: study [Seeking Alpha]Seeking Alpha
- Kailera makes history with record-breaking $625m IPO [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Weight-Loss Pill Prescriptions Near 1,400 in First Week [Yahoo! Finance]Yahoo! Finance
- Lilly's Foundayo hits 1,390 prescriptions in debut week [Yahoo! Finance Canada]Yahoo! Finance Canada
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/13/26 - Form 6-K
- 4/7/26 - Form 6-K
- 3/30/26 - Form 6-K
- NVO's page on the SEC website